Member Info for BuenaVista

Will present a damp squib.

What a terrible RNS. And terribly written.

That's his double

Agreed. As I wrote earlier today, no one seems to have been given the responsibility and, importantly, the authority (to demand provision of update content) to maintain the website up to date.

Here's last year's removed investor presentation:
https://web.archive.org/web/20220209145523/https://avacta.com/wp-content/uploads/2022/02/Feb-2022-investor-presentation.pdf

Good to know they have a communications programme. ...And that it's in red.

However I can see no changes other than the 'Introduction to Avacta' at the foot of the page has been removed
https://web.archive.org/web/20221206041411/https://avacta.com/investors/ceo-welcome/

and the linked PDF is no longer on the website:
https://avacta.com/wp-content/uploads/2022/02/Feb-2022-investor-presentation.pdf

Joe yawning and stretching, donning dressing gown and toddling off to the washroom to brush his teeth - clean and fresh! - before descendng to the basement to throw the switch on that gleaming metal box thing that folks tell him is the central controller for his in-vivo life-support system.

I question how many compounds Avacta can put through development concurrently.

There's AVA6000 of course.

Something has been happening with AVA3996, about which we expect to hear tomorrow 7am or sometime Friday.

Something is being done with TMAC and expect to hear similarly.

Then there are the two inhouse Affimer candidates.

And the 10+ other pre|CISION prodrugs that have been listed, for which patent life is expiring rapidly given all the AVA6000 and AVA3996 data that was done by Bachovchin's group(s) in the US before handover to Avacta. If these aren't licensed out some will lapse (in several years' time, but a relatively short time given how long clinical development takes) into generic opportunities and pharma companies can see that, particularly as those like AVA3996 that are analogues of out of patent drugs will need full safety, tolerability and efficacy clinical trials.

And that's without considering what else might come out of the Affimer technology platform, which has been very sp**** so far.

Avacta would need to expand massively in order to organise and fund effective development of all these 'shots on goal'.

The pipeline page is hardly selling Avacta to anyone goiing there for research. Eight pipelines, of which 3 are outside Avacta and only 3 of the 5 Avacta ones have any detail at all, with nothing for AVA3996 (in pre-clinical) or AVA028 (seemingly the most advanced of the three shown as being in 'research'). No mention of the many other pre|CISION prodrugs.

Most surprisingly, there are no links from the 4 pop-ups to all the further information about these that exists in presentation form.

Basically, I think the website isn't being maintained (no one has responsibility and authority), which means this window into Avacta isn't a good look for professional people researching Avacta's prospects.

Doesn't prove anything. HL gives reasons why a trade may not be possible "including, but not limited to, the size of your order or current market volatility".

Can just now sell 50,000 but not 100,000. This may have been what it atually was when I tried before. I wanted to be out quick before I clicked on the wrong button. anyway, 163 to sell 50,000. Had been 164, and 164.01 for smaller amounts.

Can sell 25,000 but not 50,000. Didn't try inbetween - always nervous of disengaged brain when doing this.

I didn't get one so I wouldn't know! Anyone's guess really. I suppose it might satisfy the curious invitees if they could then research who the KOLs are.

You think DE4 with C5 has already been completed?

No, nothing official

My favourite Buffetism is "Many hands make light work of piling the plate as high as it can go".

The Therapeutics text has remained the same since at least 25th May last year.

6th December was a snapshot, not when the last change(s) were made and, indeed, changes may have been made between 6th December and this morning.

CFO added to both teams... for greater financial oversight, or could Avacta be preparing to split the company...

Changes since 6th December

Therapeutics Leadership Team: Tony Gardiner (CFO) has been added.
https://web.archive.org/web/20221206051747/https://avacta.com/therapeutics/

Diagnostics Leadership Team: Tony Gardiner and Veronique Petit (Launch Diagnostics) added; Gemma Wilson (Head of QA/RA), David Wilson (Commercial Director, Diagnostics) and Marc Green (Head of Product Development, Diagnostics) removed.
https://web.archive.org/web/20221206042818/https://avacta.com/diagnostics/

Neutronic, the next dose escalation is DE4 (C5).

Only a fool would sell because there wasn't a RNS on a day when a RNS shouldn't reasonably be expected.

Well, also some explanation about C5 if MTD is to be found by the end of June after dose escalations (plural). News that it has started (and the dose level) or reason why it is delayed. It's already 5 weeks since it was announced that further dose escalations had been recommended by the SDMC.